PRO95780

DRUG5 trials

Sponsors

Genentech, Inc.

Conditions

ChondrosarcomaColorectal CancerMetastatic Colorectal CancerNon-Hodgkin's LymphomaNon-Small Cell Lung Cancer

Phase 1

A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

CompletedNCT00497497

Genentech, Inc.Colorectal Cancer

Start: 2007-10-31End: 2010-09-30Updated: 2017-05-19

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

CompletedNCT00851136

Genentech, Inc.Metastatic Colorectal Cancer

Start: 2009-05-31End: 2010-06-30Updated: 2022-12-13

Phase 2

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

CompletedNCT00480831

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2007-06-30End: 2010-08-31Updated: 2017-05-18

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

CompletedNCT00517049

Genentech, Inc.Non-Hodgkin's Lymphoma

Start: 2008-03-31End: 2009-12-31Updated: 2017-06-06

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

TerminatedNCT00543712

Genentech, Inc.Chondrosarcoma

Start: 2007-05-31End: 2008-05-05Updated: 2022-12-13